Physician profile
Ryan Wayne Chapman
NPI 1427637610
$1,507.98
in general payments reported to CMS, 2019-2025
15 companies · $696 in 2025
The $696 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $132 · 2023: $241 · 2024: $440 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,376.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $248.12 | 2024-2025 | Andexxa, Wainua |
| Abbvie INC. | $213.73 | 2023-2025 | Botox |
| Alexion Pharmaceuticals, INC. | $187.01 | 2022-2025 | Ultomiris |
| Sk Life Science, INC. | $156.85 | 2024-2025 | Xcopri |
| Penumbra, INC. | $126.47 | 2024 | Penumbra System |
| Ucb, INC. | $115.09 | 2024-2025 | Fintepla, Nayzilam, Rystiggo |
| Biogen, INC. | $114.19 | 2023-2025 | Vumerity |
| Jazz Pharmaceuticals INC. | $96.45 | 2025 | |
| Emd Serono, INC. | $91.24 | 2022-2025 | |
| Genzyme Corporation | $33.51 | 2025 | |
| Medtronic, INC. | $31.24 | 2025 | Linq II |
| Neurelis, INC. | $29.66 | 2025 | Valtoco |
| Zimmer Biomet Holdings, INC. | $22.97 | 2024 | Rosa |
| Lundbeck LLC | $22.19 | 2022 | |
| Acorda Therapeutics, INC | $19.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.